Company Overview of 3-V Biosciences, Inc.
3-V Biosciences, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing therapeutics for the treatment of infectious diseases. Its therapeutics target host cell factors required for viral infection thereby avoiding various shortcomings of traditional pathogen-directed approaches. The company was incorporated in 2006 and is based in Menlo Park, California.
1050 Hamilton Court
Menlo Park, CA 94025
Founded in 2006
Key Executives for 3-V Biosciences, Inc.
Compensation as of Fiscal Year 2012.
3-V Biosciences, Inc. Key Developments
3-V Biosciences, Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 03:20 PM
Nov 26 12
3-V Biosciences, Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 03:20 PM. Venue: Westin Copley Place, Boston, Massachusetts, United States.
3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Nov 10 12
3-V Biosciences, Inc. announced that preclinical data for its novel fatty acid synthase (FASN) inhibitors for the treatment of chronic hepatitis C virus (HCV) infection will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases being held November 9-13 in Boston, Massachusetts. The company's FASN inhibitors for the treatment of HCV are designed to have broad-spectrum activity, a high barrier to resistance and the ability to combine with direct-acting antivirals, such as nucleotide/nucleoside inhibitors, protease inhibitors, NS5a inhibitors and other mechanisms of action currently in development. Data characterizing the preclinical antiviral activity of 3-V's FASN inhibitors will be featured in oral and poster presentations during The Liver Meeting. Highlights of these data include: Orally bioavailable representative molecules are potent and specific, with IC50s in the 5-50nM range; Inhibitors have demonstrated excellent exposure and low toxicity in rodents associated with prolonged in vivo suppression of FASN; Antiviral activity against wild-type Genotype 1a, 1b and 2a replicons; and Antiviral activity against mutant HCV replicons resistant to NS3, NS4b, NS5a and NS5b inhibitors. The company's FASN inhibitors are a chemically diverse set of potent, specific, reversible molecules with an excellent range of pharmaceutical properties. The company has filed multiple worldwide patent applications covering these inhibitors. 3-V's HCV program is on track for an IND in the first quarter of 2013 and the company anticipates clinical proof-of-concept data by year-end 2013.
3-V Biosciences, Inc. Appoints Douglas I. Buckley as Vice President of Biology
Jun 29 12
3-V Biosciences, Inc. announced the appointment of Douglas Buckley, PhD, as Vice President of Biology. Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed products and many more in clinical development. Dr. Buckley joins 3-V from Exelixis, Inc., where he served most recently as Vice President of Biochemistry. In that role, he led research and discovery teams responsible for delivering over thirty IND-ready compounds to Exelixis' internal pipeline and to external partnerships.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|